Pacira BioSciences faces significant risk as generic challenges threaten Exparel, its flagship product responsible for 78% of 2024 revenue. PCRX's complex formulation, robust patent estate, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback